Kissei Pharmaceutical Halts Tavneos Use Amid Deaths

Kissei Pharmaceutical has urged physicians across Japan to stop prescribing its vasculitis drug Tavneos after 20 patients died from serious liver dysfunction, triggering a swift regulatory response and fresh scrutiny of the drug's safety profile in global markets. Structured plan for Kissei Pharmaceutical Halts Tavneos Use Amid Deaths: here is what business development teams, investors, and competitive intelligence units need to know as the situation continues to evolve.

Key Takeaways

Kissei Pharmaceutical confirmed 20 deaths in Japan linked to Tavneos (avacopan), with liver dysfunction identified as the primary cause of fatalities, prompting the company to ask doctors to halt new prescriptions.
Japan's Ministry of Health reversed course on May 21, 2026, restoring new-patient access to Tavneos but under substantially tougher safety warnings and enhanced monitoring requirements.
The FDA has sought to pull Tavneos from the US market, while European regulators are investigating data-integrity concerns, creating a fragmented global regulatory posture that directly affects competitive positioning and licensing valuations.
Amgen, which holds US and ex-Japan commercialization rights, continues to defend the drug's benefit-risk profile despite the Japanese fatalities, setting up a divergence in regulatory strategy between its operations and those of its Japanese partner.

What Happened?

Kissei Pharmaceutical announced that 20 individuals who received Tavneos for ANCA-associated vasculitis had died in Japan, with post-mortem and clinical investigations pointing to serious liver dysfunction as the proximate cause. The company moved quickly, issuing a formal request to physicians to suspend use of the drug in both new and existing patients pending further review.

The deaths were reported through Japan's pharmacovigilance system and were significant enough to trigger intervention by the country's regulatory authorities. According to reporting by Reuters, the fatalities involved serious liver injuries that developed during treatment with the complement C5a receptor antagonist. The Asahi Shimbun confirmed that Kissei formally urged doctors to halt prescriptions, and Japan's health ministry subsequently ordered the company to add strengthened warnings to the product label.

On May 21, 2026, the Japanese government reversed its earlier restriction, allowing Tavneos to be prescribed to new patients again under revised labeling that includes enhanced hepatic monitoring requirements and explicit risk warnings. This partial restoration signals that regulators judged the drug's benefit-risk profile to remain favorable for a defined patient population, provided safeguards are in place.

What Does This Mean for Pharma BD and Regulatory Teams?

The Tavneos situation creates a complex, multi-jurisdictional risk calculus. The FDA has taken an aggressive stance, seeking to remove the drug from the US market entirely, while Japan has opted for a warning-and-monitoring approach. European regulators are separately examining data-integrity questions. For BD teams evaluating in-licensing opportunities or partnership structures involving complement inhibitors, these divergent regulatory outcomes must be modeled as discrete scenarios rather than a single global forecast.

Kissei's commercial exposure in Japan is now constrained by the revised labeling requirements, which will likely reduce prescribing volume and increase the cost of pharmacovigilance compliance. The reputational damage extends beyond the immediate financial hit: Kissei's credibility as a commercialization partner for novel therapies may be scrutinized in future deal negotiations, particularly by larger pharmaceutical companies evaluating co-development agreements in the rare-disease space.

For Amgen, the stakes are different but equally acute. The company continues to defend Tavneos's benefit-risk profile in the US and Europe, even as its Japanese partner has accepted enhanced restrictions. This divergence could complicate global lifecycle-management strategy and create tension in the partnership structure. Investors should watch for any amendment to the Kissei-Amgen licensing agreement, particularly around milestone payments, royalty rates, or termination clauses tied to regulatory actions.

Competitors in the ANCA-associated vasculitis space, including companies developing alternative complement pathway inhibitors, are likely to use the Tavneos safety signal as a point of differentiation in their own regulatory filings and commercial messaging. Any company with a late-stage asset in this indication should proactively address the liver-safety question in its clinical data package.

Frequently Asked Questions

What is Tavneos and what does it treat?

Tavneos (avacopan) is an oral complement C5a receptor antagonist approved for the treatment of ANCA-associated vasculitis, a rare autoimmune disease that causes inflammation of small blood vessels. It was developed as an adjunct to standard immunosuppressive therapy, with the goal of reducing reliance on high-dose glucocorticoids. The drug is commercialized by Kissei Pharmaceutical in Japan and by Amgen in the United States and other ex-Japan markets.

How many deaths have been linked to Tavneos in Japan?

Kissei Pharmaceutical confirmed that 20 patients who received Tavneos in Japan died, with liver dysfunction identified as the primary safety concern. The deaths were reported through Japan's post-marketing pharmacovigilance system, prompting the company to request that physicians suspend use of the drug pending investigation. Japanese regulators subsequently restored access under revised labeling with enhanced safety warnings.

Has Tavneos been withdrawn from the market?

Not entirely. In Japan, new-patient access to Tavneos was temporarily suspended and then restored on May 21, 2026 under stricter labeling and monitoring requirements. In the United States, the FDA has sought to pull the drug from the market, while European regulators are conducting a separate review of data-integrity concerns. The drug remains available in some jurisdictions but under heightened regulatory scrutiny.

What should investors watch for next?

Key catalysts include the outcome of the FDA's market-withdrawal proceeding, the European Medicines Agency's data-integrity review, any revision to the Kissei-Amgen partnership agreement, and quarterly prescription-volume data from Japan reflecting the impact of revised labeling. Investors should also monitor whether additional fatalities or serious adverse events are reported in other markets where Tavneos is prescribed.

Related profiles

TAVNEOS